Welcome to our dedicated page for Amryt Pharma Plc news (Ticker: AMYT), a resource for investors and traders seeking the latest updates and insights on Amryt Pharma Plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amryt Pharma Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amryt Pharma Plc's position in the market.
Amryt Pharma has announced a distribution agreement with Medison Pharma Canada for Myalepta® (metreleptin) in Canada. This agreement finalizes previous multi-regional contracts for the distribution of Myalepta® and other products, aimed at enhancing access to rare disease treatments. CEO Dr. Joe Wiley emphasized the importance of expanding their commercial assets and leveraging Medison's expertise. Myalepta® is already approved for treating leptin deficiency in patients with lipodystrophy in the US and EU.
Amryt announces it will release its unaudited Q4 2020 and FY 2020 financial results on March 4, 2021, at 0700 EST. A conference call for analysts and investors is scheduled for 0830 EST the same day. In addition to its financial performance, Amryt focuses on developing innovative therapeutics for rare diseases, including two commercial products, Myalept and Juxtapid, and its lead development candidate Filsuvez. This announcement contains inside information under the Market Abuse Regulation.
Amryt has entered into multi-regional distribution agreements with Medison Pharma for its products in Canada and Israel. The agreements will allow Medison to distribute Juxtapid (lomitapide) in Canada and Lojuxta (lomitapide) along with Myalept (metreleptin) in Israel. Dr. Joe Wiley, CEO of Amryt, emphasized the significance of these partnerships in expanding their reach in the rare disease market. The company is progressing with its lead candidate, Filsuvez (Oleogel-S10), which targets Epidermolysis Bullosa, with positive results reported from earlier trials.
Amryt Pharma has announced a distribution deal with Swixx BioPharma for its product Lojuxta® (lomitapide) across 17 jurisdictions in Central and Eastern Europe. Starting October 2020, Swixx will distribute Lojuxta in countries including Albania and Poland, expanding to include the Czech Republic and Hungary in January 2021. This agreement builds on their existing partnership for Myalepta® (metreleptin). CEO Joe Wiley stated this move will enhance commercial performance and increase access to treatment for patients.
Amryt Pharma is set to announce its Q3 financial results on November 5, 2020. The unaudited results will cover the period ending September 30, 2020, and a conference call for analysts and investors is scheduled for the same day at 1430 GMT / 0930 ET. The company is focused on developing treatments for rare diseases, with commercial products approved for specific conditions. The webcast will be accessible for stakeholders, providing insights into the company’s performance and future strategies.
On October 9, 2020, Amryt Pharma PLC received notification from UBS Asset Management, indicating a significant change in voting rights. UBS's holdings dropped from 6.13% to 6.12%, with the date of the threshold crossed being October 7, 2020. The report stated that UBS held a total of 162,801,593 voting rights, with 9,967,620 of those rights derived from financial instruments. This notification reflects a minor adjustment in UBS's position but retains their significant interest in the company.
Amryt Pharma announced the exercise of options by a former employee, leading to the issuance of 72,953 ordinary shares. Following this, the total issued share capital stands at 167,593,296 shares, with 4,791,703 shares held in treasury. This adjustment results in a new total of 162,801,593 voting rights. The company also holds 8,966,520 zero-cost warrants. The statement emphasizes the company's focus on rare diseases and its ongoing clinical developments.
Amryt Pharma reported a significant change in major shareholdings as UBS Asset Management - O'Connor acquired a total of 6.13% voting rights in the company. This includes 2.60% direct voting rights from 4,229,753 shares and 3.53% from financial instruments. The change was effective as of September 22, 2020, and was officially notified on September 29, 2020. The investment reflects UBS Group AG's strategic interest in Amryt Pharma's potential growth and value in the market.
On September 21, 2020, Amryt Pharma announced that an institutional investor exercised subscription rights for 4,229,753 zero-cost warrants. These warrants were issued during the acquisition of Aegerion in September 2019. The company will issue the same number of new ordinary shares at £0.06 each, which will be admitted for trading on September 22, 2020. Post-exercise, Amryt's issued share capital will total 167,593,296 shares, with 162,728,640 voting rights available for shareholders' interest notifications.
